title: Betaine dose and treatment intervals in therapy for homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency.
authors.affiliation: Department of Pediatrics, Hiroshima University School of Medicine, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Sakura
authors.forename: H
authors.initials: H
authors.lastname: Ono
authors.forename: S
authors.initials: S
authors.lastname: Nomura
authors.forename: H
authors.initials: H
authors.lastname: Ueda
authors.forename: N
authors.initials: N
authors.lastname: Fujita
mesh_terms: D045103:5,10-Methylenetetrahydrofolate Reductase (FADH2); D000328:Adult; D001622:Betaine / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006712:Homocystinuria / Q000188:drug therapy*; D006801:Humans; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D010088:Oxidoreductases / Q000172:deficiency*
chemical_list: D001622:Betaine; D010088:Oxidoreductases; D045103:5,10-Methylenetetrahydrofolate Reductase (FADH2); D042965:Methylenetetrahydrofolate Reductase (NADPH2)